Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D06DUS
|
|||
| Former ID |
DNCL003505
|
|||
| Drug Name |
PVX-410
|
|||
| Indication | Multiple myeloma [ICD-11: 2A83; ICD-10: C90.0] | Phase 2 | [1], [2], [3], [4] | |
| Triple negative breast cancer [ICD-11: 2C60-2C65] | Phase 2 | [5] | ||
| Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-10: C76-C80; ICD-9: 140-229] | Phase 1 | [6] | ||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | SLAM family member 7 SLAMF7 (CS1) | Target Info | Modulator | [7], [8] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 2 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 3 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 4 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 5 | ClinicalTrials.gov (NCT04634747) A Single-Arm, Open-Label, Multi-Center Phase II Study to Evaluate the Combination of PVX-410 + Pembrolizumab + Chemotherapy for Frontline Therapy of Metastatic, PD-L1+ Triple-Negative Breast Cancer (TNBC) in HLA-A2-Positive Patients. U.S. National Institutes of Health. | |||
| REF 6 | ClinicalTrials.gov (NCT01718899) Phase 1/2a Study of Cancer Vaccine to Treat Smoldering Multiple Myeloma. U.S. National Institutes of Health. | |||
| REF 7 | Market watch: Upcoming catalysts in Q2 2015. Nat Rev Drug Discov. 2015 Apr;14(4):228. | |||
| REF 8 | Combinatorial efficacy of anti-CS1 monoclonal antibody elotuzumab (HuLuc63) and bortezomib against multiple myeloma. Mol Cancer Ther. 2009 Sep;8(9):2616-24. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.